I am a
Home I AM A Search Login

Papers of the Week

2020 Nov 26

Dermatol Ther

Effectiveness and safety of lidocaine patch 5% to treat herpes zoster acute neuralgia and to prevent post-herpetic neuralgia.


Bianchi L, Piergiovanni C, Marietti R, Renzini M, Gori F, Hansel K, Tramontana M, Stingeni L
Dermatol Ther. 2020 Nov 26:e14590.
PMID: 33244838.


Herpes zoster is often associated to acute neuralgia and post-herpetic neuralgia. Their therapeutic management is still challenging: among therapeutic options, lidocaine patch 5% was rarely used in acute neuralgia on lesional skin, and its efficacy to prevent post-herpetic neuralgia was never studied. The efficacy and tolerability of lidocaine patch 5% was evaluated in 38 patients with acute neuralgia (19) and post-herpetic neuralgia (19). Pain intensity was investigated using DN4 questionnaire and NRS-11 scale at baseline and at week 2, 4, and 8. The use of rescue therapy was also evaluated. A significant reduction of DN4 and NRS-11 was observed already at W2, with further improvement at W4 and W8. A complete response to treatment (DN4 and NRS-11 = 0) at week 8 was higher in patients with acute neuralgia (63.2%) than post-herpetic neuralgia (31.6%). Rescue therapy gradually decreased in acute neuralgia patients from week 2 (57.9%) to week 8 (10.5%), with only 2 patients needing neuroleptics. In post-herpetic neuralgia patients rescue therapy remained stable (68.4%). According to our results, lidocaine patch 5% applied on lesional skin was well tolerated and ensured a rapid pain relief in acute neuralgia; if early used, it prevented post-herpetic neuralgia in almost all patients. This article is protected by copyright. All rights reserved.